Modernatx, Inc.

Moderna Therapeutics, Inc.

Justin Guild

Jeff Lynn Ellsworth

Antonin De Fougerolles

Sayda Mahgoub Elbashir

Stephen G Hoge

Tirtha Chakraborty

Stephane Bancel

Jason P Schrum

Atanu Roy

Kenechi Ejebe

Kristy M Wood

Paul Hatala

Susan Whoriskey

Matthias John

Ron Weiss

Joseph Beene Bolen

Francine M Gregoire

The invention relates to compositions including polynucleotides encoding polypeptides which have been chemically modified by replacing the uridines with 1-methyl-pseudouridine to improve one or more of the stability and/or clearance in tissues, receptor uptake and/or kinetics, cellular access by the compositions, engagement with translational machinery, mRNA half-life, translation efficiency, immune evasion, protein production capacity, secretion efficiency, accessibility to circulation, protein half-life and/or modulation of a cell's status, function, and/or activity.

Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins

The invention relates to a pharmaceutical composition including a plurality of lipid nanoparticles having a mean particle size of between 80 nm and 160 nm and containing an mRNA encoding a polypeptide. The lipid nanoparticles include a cationic lipid, a neutral lipid, a cholesterol, and a PEG lipid. The mRNA contains a 5'-cap, 5&#x2032;-UTR, a 3&#x2032;-UTR, and a poly-A region with at least 100 nucleotides.

Modified Polynucleotides for the production of biologics and proteins associated with human disease

A pharmaceutical composition which has a plurality of lipid nanoparticles that has a mean particle size of between 80 nm and 160 nm and contains a modified mRNA encoding a polypeptide. The lipid nanoparticles include a cationic lipid, a neutral lipid, a cholesterol, and a PEG lipid. The mRNA contains a 5'-cap, 5&#x2032;-UTR, N1-methyl-pseudouridine, a 3&#x2032;-UTR, and a poly-A region with at least 100 nucleotides.

Modified polynucleotides for the production of secreted proteins

In vivo production of proteins

The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.

Modified polynucleotides

Modified polynucleotides for the production of oncology-related proteins and peptides

The present disclosure describes compositions including polynucleotides encoding polypeptides which have been chemically modified by replacing the uridines with 5-methoxy-uridines to improve the compositions, engagement with translational machinery, mRNA half-life, translation efficiency, immune evasion, protein production capacity, secretion efficiency, accessibility to circulation, protein half-life and/or modulation of a cell's status, protein half-life and/or modulation of a cell's status function, and/or activity.

The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotide molecules encoding low density lipoprotein receptor comprising at least one mutation (e.g., an LDLR signally enhancing mutation).

Polynucleotides encoding low density lipoprotein receptor

Modified polynucleotides for the production of proteins

Modified polynucleotides for the production of biologics and proteins associated with human disease

Modified polynucleotides for the production of proteins associated with human disease

Growing community of inventors

Framingham, MA, United States of America

Justin Guild